FORM 6-K
 

 

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

 

Report of Foreign Issuer

 

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 


For period ending August 2010
 

GlaxoSmithKline plc
(Name of registrant)
 
 

 

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
 
 

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
 
 

Form 20-F x Form 40-F
 

 --

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
 
 
Yes No x
  --

Financial Services Authority

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
   

1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:

GlaxoSmithKline Plc

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Yes

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

  

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

  

An event changing the breakdown of voting rights

  

Other (please specify):

    

3. Full name of person(s) subject to the
notification obligation:

Legal & General Group Plc (L&G)

4. Full name of shareholder(s)
(if different from 3.):

Legal & General Assurance (Pensions Management) Limited (PMC)

5. Date of the transaction and date on
which the threshold is crossed or
reached:

16 August 2010

6. Date on which issuer notified:

17 August 2010

7. Threshold(s) that is/are crossed or
reached:

L&G (From 4% to 3%)



8. Notified details:

A: Voting rights attached to shares

Class/type of
shares

if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of voting rights
     

Direct

Indirect

Direct

Indirect

Ordinary 25p

208,149,243
 
(As on 04/08/2010)

207,246,143

207,246,143

 

3.99%

  
 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date

Exercise/
Conversion Period

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights
         
 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date

Exercise/
Conversion period

Number of voting rights instrument refers to

% of voting rights

         

Nominal

Delta
       
 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

207,246,143

3.99%


9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:


Legal & General Group Plc (Direct and Indirect) (Group)

 

Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect)

 

Legal & General Investment Management Limited (Indirect) (LGIM)

 

Legal & General Group Plc (Direct) (L&G) ( 207,246,143 - 3.99%= LGAS, LGPL & PMC)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD) ( 173,534,467 – 3.34%= PMC)

Legal & General Insurance Holdings Limited (Direct) (LGIH)

Legal & General Assurance (Pensions Management) Limited (PMC) ( 173,534,467 – 3.34%= PMC)

Legal & General Assurance Society Limited (LGAS & LGPL)

 

Legal & General Pensions Limited (Direct) (LGPL)

 

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease
to hold:

N/A

12. Date on which proxy holder will cease to hold
voting rights:

N/A
 

13. Additional information:

Notification using the total voting rights figure of 5,192,669,600

14. Contact name:

Paul Toon (LGIM)

15. Contact telephone number:

020 3124 3854


 



 



SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
 

GlaxoSmithKline plc
(Registrant)
 
 

Date: August 18 2010

By: VICTORIA WHYTE

------------------

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc